YE6144|西域试剂

YE6144,95.0%

产品编号：Bellancom-150095| 分子式：C₂₁H₂₇ClFN₇O| 分子量：447.94

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-150095		￥5200.00	杭州北京（现货）
Bellancom-150095		￥15500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

YE6144

产品介绍

YE6144 是一种典型的干扰素调节因子 5 (IRF5) 抑制剂。YE6144 通过抑制 IRF5 磷酸化选择性抑制 IRF5 活性。

生物活性

YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation.

体外研究

YE6144 (1 or 3 μM; 30 min) inhibits the phosphorylation of IRF5 in both human PBMCs and mouse splenocytes.
YE6144 (0-10 μM; 30 min) inhibits the production of type I IFNs with an IC₅₀ of approximately 0.09 μM in human HC PBMCs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human HC PBMCs and mouse WT splenocytes
Concentration:	1 μM (PBMCs) and 3 μM (splenocytes)
Incubation Time:	30 min
Result:	Inhibited the phosphorylation of IRF5.

RT-PCR

Cell Line:	Mouse WT splenocytes
Concentration:	3 μM
Incubation Time:	30 min
Result:	Induction of type I IFN genes, Ifnb1 and Ifna stimulated by TLR7 ligands or TLR9 ligands was remarkably weakened.

体内研究
(In Vivo)

YE6144 (40.0 mg/kg; s.c.; once) suppresses the progression of mouse systemic lupus erythematosus.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NZB/W F1 mouse model of systemic lupus erythematosus (SLE)
Dosage:	40.0 mg/kg
Administration:	Subcutaneous injection, once
Result:	Suppressed the exacerbation of autoantibody production. Splenomegaly and renal dysfunction were also suppressed by the treatment after disease onset.

体内研究

YE6144 (40.0 mg/kg; s.c.; once) suppresses the progression of mouse systemic lupus erythematosus.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NZB/W F1 mouse model of systemic lupus erythematosus (SLE)
Dosage:	40.0 mg/kg
Administration:	Subcutaneous injection, once
Result:	Suppressed the exacerbation of autoantibody production. Splenomegaly and renal dysfunction were also suppressed by the treatment after disease onset.

体内研究

YE6144 (40.0 mg/kg; s.c.; once) suppresses the progression of mouse systemic lupus erythematosus.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NZB/W F1 mouse model of systemic lupus erythematosus (SLE)
Dosage:	40.0 mg/kg
Administration:	Subcutaneous injection, once
Result:	Suppressed the exacerbation of autoantibody production. Splenomegaly and renal dysfunction were also suppressed by the treatment after disease onset.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (279.06 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2324 mL	11.1622 mL	22.3244 mL
5 mM	0.4465 mL	2.2324 mL	4.4649 mL
10 mM	0.2232 mL	1.1162 mL	2.2324 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.64 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.64 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明